利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.02 秒)

    METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION
    1.
    发明公开
    METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION 审中-公开
    VERFAHREN UND ZUSAMMENSETZUNGEN ZUR HEMMUNG VON TRANSPLANTATABSTOSSUNG

    公开(公告)号：EP2473523A2

    公开(公告)日：2012-07-11

    申请号：EP10752959.6

    申请日：2010-08-31

    申请人： Amplimmune, Inc.

    发明人： LANGERMANN, Solomon ,  LIU, Linda

    IPC分类号： C07K14/705 ,  G01N33/68 ,  C07K16/28 ,  G01N33/564 ,  G01N33/50 ,  A61K38/17 ,  A61K47/48

    CPC分类号： C07K14/70532 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/1709 ,  A61K39/44 ,  C07K16/2827 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/72 ,  C07K2319/30 ,  C07K2319/32 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2800/52

    摘要： Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.

    摘要翻译： 提供了调节受试者中免疫应答的方法。 优选的实施方案提供用于减少或抑制受试者，优选人受试者的移植排斥的方法和组合物。 通过施用有效量的B7-H4多肽，其片段或融合物来抑制或降低免疫细胞的生物学活性或减少移植部位的促炎症分子的量，可以抑制或减少受试者的移植排斥反应。 Th1，Th17和Th22细胞是可以被B7-H4多肽，融合蛋白或其片段抑制或减少炎症的靶向的示例性T细胞。

    PD-1 ANTAGONISTS AND METHODS OF USE THEREOF
    3.
    发明公开
    PD-1 ANTAGONISTS AND METHODS OF USE THEREOF 审中-公开
    PD-1拮抗剂和申请流程。

    公开(公告)号：EP2324055A2

    公开(公告)日：2011-05-25

    申请号：EP09791915.3

    申请日：2009-08-25

    申请人： Amplimmune, Inc.

    发明人： LANGERMANN, Solomon ,  LIU, Linda

    IPC分类号： C07K14/47

    CPC分类号： A61K39/39 ,  A61K31/664 ,  A61K38/00 ,  A61K38/177 ,  A61K39/3955 ,  A61K39/39558 ,  C07K14/4748 ,  C07K14/521 ,  C07K14/70532 ,  C07K14/7158 ,  C07K2319/33 ,  C12N15/62 ,  Y02A50/385 ,  Y02A50/409 ,  Y02A50/411

    摘要： Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by binding to and blocking PD-I to prevent or reduce inhibitory signal transduction, or by binding to Hgands of PD-I such as PD-L1, thereby preventing (in whole or in part) the ligand from binding to PD-I to deliver an inhibitory signal. The immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting). In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

    SIMULTANEOUS INHIBITION OF PD-L1/PD-L2
    7.
    发明公开
    SIMULTANEOUS INHIBITION OF PD-L1/PD-L2 审中-公开
    的同时抑制PD-L1 / PD-L2

    公开(公告)号：EP2504028A2

    公开(公告)日：2012-10-03

    申请号：EP10833892.2

    申请日：2010-11-24

    申请人： Amplimmune, Inc.

    发明人： LANGERMANN, Solomon

    IPC分类号： A61K39/00 ,  A61P37/08

    CPC分类号： A61K38/17 ,  C07K2319/30

    摘要： Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

    PD-I ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE
    8.
    发明公开
    PD-I ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE 审中-公开
    PD-1拮抗剂和方法感染性疾病的治疗

    公开(公告)号：EP2328919A2

    公开(公告)日：2011-06-08

    申请号：EP09807659.9

    申请日：2009-08-25

    申请人： Amplimmune, Inc.

    发明人： LANGERMANN, Solomon

    IPC分类号： C07K14/47 ,  C07K14/705 ,  C07K14/52 ,  C07K14/715 ,  A61K38/17

    CPC分类号： A61K39/39 ,  A61K31/664 ,  A61K38/00 ,  A61K38/177 ,  A61K39/3955 ,  A61K39/39558 ,  C07K14/4748 ,  C07K14/521 ,  C07K14/70532 ,  C07K14/7158 ,  C07K2319/33 ,  C12N15/62 ,  Y02A50/385 ,  Y02A50/409 ,  Y02A50/411

    摘要： Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by binding to and blocking PD-I to prevent or reduce inhibitory signal transduction, or by binding to Hgands of PD-I such as PD-L1, thereby preventing (in whole or in part) the ligand from binding to PD-I to deliver an inhibitory signal. The immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting). In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

    ANTI-B7-H4 ANTIBODIES AND THEIR USES
    10.
    发明公开
    ANTI-B7-H4 ANTIBODIES AND THEIR USES 有权
    抗B7-H4抗体和用途

    公开(公告)号：EP2756094A1

    公开(公告)日：2014-07-23

    申请号：EP12824657.6

    申请日：2012-08-15

    申请人： Amplimmune, Inc.

    发明人： LIU, Linda ,  MARSHALL, Shannon ,  LANGERMANN, Solomon

    IPC分类号： C12P21/08 ,  C07K16/00 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  C07K16/30 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77

    摘要： The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages ("TAMs") so as to alter their activity and/or decrease T AM -mediated immune suppression.